Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571993 | PMC |
| http://dx.doi.org/10.1186/s13054-024-05154-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative evaluation of high-flow nasal cannula (HFNC) and conventional oxygen therapy (COT) in infants after non-cardiac surgery: Study protocol of a randomized controlled trial.
PLoS One
January 2025
Department of Anesthesiology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Background: Literature regarding the advantages of HFNC in infants for ensuring oxygen supply after non-cardiac surgery is insufficient. The purpose of our study is to compare COT vs. HFNC on postoperative outcomes in infants undergoing non-cardiac surgery.
View Article and Find Full Text PDFResponse to: "Inhalation NO in the HFNC group may result in a meaningless extension of survival time".
Crit Care
January 2025
Department of Critical Care Medicine, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.
[High flow nasal cannula: is it a risk factor of bronchopulmonary dysplasia and retinopathy of premature?].
Andes Pediatr
August 2024
Servicio de Neonatologia, Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.
Article Synopsis
- Observational studies show that using high-flow nasal cannula (HFNC) from 2013-2016 is linked to longer oxygen therapy duration, increased rates of bronchopulmonary dysplasia (BPD), and retinopathy of prematurity (ROP).
- The study aimed to analyze neonatal outcomes for very preterm newborns with HFNC between 2017-2021, using statistical methods to compare cases with controls based on weight and gestational age.
- Results indicated a significant rise in BPD and ROP in the HFNC group, alongside higher respiratory support, with logistic regression confirming HFNC use is associated with greater risks for both conditions, suggesting the need for a quality improvement program to enhance HFNC
Serial biomarker measurements may be helpful to predict the successful application of high flow nasal cannula in COVID-19 pneumonia patients.
Sci Rep
January 2025
The Queen's Medical Center, 1301 Punchbowl Street, QET 4M, Honolulu, Hawai'i, 96813, USA.
High flow nasal cannula (HFNC) can reduce the need for intubation in patients with coronavirus disease-19 (COVID-19) pneumonia induced acute hypoxemic respiratory failure (AHRF), but predictors of HFNC success could be characterized better. C-reactive protein (CRP) and D-dimer are associated with COVID-19 severity and progression. However, no one has evaluated the use of serial CRP and D-dimer ratios to predict HFNC success.
View Article and Find Full Text PDF[Application progress of ROX index in evaluating the efficacy of pediatric high-flow nasal cannula oxygen therapy].
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
November 2024
Department of Emergency/Critical Medicine, Children's Hospital Affiliated to Nanjing Medical University, Nanjing 210008, Jiangsu, China. Corresponding author: Miao Hongjun, Email:
Respiratory support is one of the key technologies for treating pediatric respiratory diseases. High-flow nasal cannula oxygen therapy (HFNC) represents a novel method of assisted respiratory support. The commonly used indicator for assessing HFNC efficacy in clinical practice is oxygenation index (PaO/FiO).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!